RU2559083C9 - Композиции для непрерывного введения ингибиторов допа-декарбоксилазы - Google Patents
Композиции для непрерывного введения ингибиторов допа-декарбоксилазы Download PDFInfo
- Publication number
- RU2559083C9 RU2559083C9 RU2011149976/15A RU2011149976A RU2559083C9 RU 2559083 C9 RU2559083 C9 RU 2559083C9 RU 2011149976/15 A RU2011149976/15 A RU 2011149976/15A RU 2011149976 A RU2011149976 A RU 2011149976A RU 2559083 C9 RU2559083 C9 RU 2559083C9
- Authority
- RU
- Russia
- Prior art keywords
- levodopa
- carbidopa
- composition
- arginine
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 183
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 title description 8
- 229960004205 carbidopa Drugs 0.000 claims abstract description 217
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 215
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 202
- 229960004502 levodopa Drugs 0.000 claims abstract description 173
- 239000007788 liquid Substances 0.000 claims abstract description 55
- 239000004475 Arginine Substances 0.000 claims abstract description 54
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 49
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 27
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 18
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 9
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 8
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 7
- 206010034010 Parkinsonism Diseases 0.000 claims abstract description 7
- 208000005793 Restless legs syndrome Diseases 0.000 claims abstract description 5
- 208000008039 Secondary Parkinson Disease Diseases 0.000 claims abstract description 5
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 4
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 38
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 23
- 150000001483 arginine derivatives Chemical class 0.000 claims description 22
- 229960003337 entacapone Drugs 0.000 claims description 22
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 18
- 229960000911 benserazide Drugs 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 9
- 229960004603 tolcapone Drugs 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 6
- 208000025966 Neurological disease Diseases 0.000 abstract description 4
- 206010033799 Paralysis Diseases 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 219
- 239000000243 solution Substances 0.000 description 59
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 54
- 235000009697 arginine Nutrition 0.000 description 46
- -1 propionic acid monohydrate Chemical class 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 24
- 229960003638 dopamine Drugs 0.000 description 23
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 20
- 241000282887 Suidae Species 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 14
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- 229930064664 L-arginine Natural products 0.000 description 11
- 235000014852 L-arginine Nutrition 0.000 description 11
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 10
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- 102000010909 Monoamine Oxidase Human genes 0.000 description 10
- 108010062431 Monoamine oxidase Proteins 0.000 description 10
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940001607 sodium bisulfite Drugs 0.000 description 10
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002033 PVDF binder Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 241000255969 Pieris brassicae Species 0.000 description 7
- 239000003954 decarboxylase inhibitor Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940001089 sinemet Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229960002885 histidine Drugs 0.000 description 6
- 229940089964 lodosyn Drugs 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 5
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 5
- 229960003946 selegiline Drugs 0.000 description 5
- 229940103422 stalevo Drugs 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000037317 transdermal delivery Effects 0.000 description 5
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 4
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000019430 Motor disease Diseases 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 230000005264 electron capture Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 3
- 229960004644 moclobemide Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229960000245 rasagiline Drugs 0.000 description 3
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 3
- 229950002652 safinamide Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 2
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 229940052036 carbidopa / levodopa Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940087613 comtan Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- IVYOMTNVXXPNCD-LBPRGKRZSA-N ethyl (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoate Chemical group CCOC(=O)[C@](C)(Cc1ccc(O)c(O)c1)NN IVYOMTNVXXPNCD-LBPRGKRZSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17951109P | 2009-05-19 | 2009-05-19 | |
| US61/179,511 | 2009-05-19 | ||
| PCT/IL2010/000400 WO2010134074A1 (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115064A Division RU2678839C2 (ru) | 2009-05-19 | 2010-05-17 | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2011149976A RU2011149976A (ru) | 2013-06-27 |
| RU2559083C2 RU2559083C2 (ru) | 2015-08-10 |
| RU2559083C9 true RU2559083C9 (ru) | 2016-01-20 |
Family
ID=42320738
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115064A RU2678839C2 (ru) | 2009-05-19 | 2010-05-17 | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| RU2011149976/15A RU2559083C9 (ru) | 2009-05-19 | 2010-05-17 | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| RU2019101159A RU2019101159A (ru) | 2009-05-19 | 2019-01-16 | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115064A RU2678839C2 (ru) | 2009-05-19 | 2010-05-17 | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019101159A RU2019101159A (ru) | 2009-05-19 | 2019-01-16 | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8193243B2 (enExample) |
| EP (3) | EP3192500B1 (enExample) |
| JP (3) | JP5643297B2 (enExample) |
| KR (2) | KR101641401B1 (enExample) |
| CN (2) | CN104546700B (enExample) |
| AR (3) | AR078413A1 (enExample) |
| AU (1) | AU2010250766B2 (enExample) |
| BR (1) | BRPI1011031B8 (enExample) |
| CA (1) | CA2761624C (enExample) |
| CL (1) | CL2011002895A1 (enExample) |
| CY (1) | CY1119495T1 (enExample) |
| DK (2) | DK2432454T3 (enExample) |
| ES (2) | ES2840748T3 (enExample) |
| HR (2) | HRP20170805T1 (enExample) |
| HU (2) | HUE033388T2 (enExample) |
| IL (1) | IL216383A (enExample) |
| LT (1) | LT2432454T (enExample) |
| MX (2) | MX2011012315A (enExample) |
| NZ (1) | NZ596963A (enExample) |
| PL (2) | PL2432454T3 (enExample) |
| PT (2) | PT3192500T (enExample) |
| RU (3) | RU2678839C2 (enExample) |
| SG (3) | SG10201709016RA (enExample) |
| SI (1) | SI2432454T1 (enExample) |
| WO (1) | WO2010134074A1 (enExample) |
| ZA (1) | ZA201109037B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN192600B (enExample) * | 1996-10-18 | 2004-05-08 | Hoechst Celanese Corp | |
| RU2678839C2 (ru) | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| PL2640358T3 (pl) | 2010-11-15 | 2018-06-29 | Neuroderm Ltd | Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji |
| NZ703341A (en) | 2012-06-05 | 2016-11-25 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| CN103845318A (zh) * | 2012-12-07 | 2014-06-11 | 天津市汉康医药生物技术有限公司 | 恩他卡朋分散片 |
| BR112015022390A8 (pt) * | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| KR102457026B1 (ko) * | 2013-11-05 | 2022-10-21 | 신애질 코포레이션 | 입을 통한 연속적 약물 전달 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| CN106413754B (zh) * | 2014-03-13 | 2019-11-29 | 纽罗德姆有限公司 | 多巴脱羧酶抑制剂组合物 |
| WO2016036308A1 (en) | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| TWI755257B (zh) | 2014-10-21 | 2022-02-11 | 美商艾伯維有限公司 | 卡比多巴及左旋多巴之前藥及使用方法 |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| BR112018010564A2 (pt) | 2015-11-24 | 2018-11-21 | Neuroderm Ltd. | composições farmacêuticas compreendendo levodopa amida e usos das mesmas |
| WO2017177262A1 (en) * | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| US10064834B2 (en) | 2016-05-09 | 2018-09-04 | Texas Tech University System | Carbidopa for the treatment of cancer |
| CN110753538A (zh) | 2017-06-05 | 2020-02-04 | 迪兹林制药公司 | 左旋多巴输注溶液 |
| US20230123806A1 (en) * | 2017-07-07 | 2023-04-20 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
| CN111954523A (zh) * | 2018-03-29 | 2020-11-17 | 艾维制药有限责任公司 | 左旋多巴分次剂量组合物及用途 |
| EP3880210A1 (en) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| WO2020252257A1 (en) * | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| JP2023538859A (ja) * | 2020-08-31 | 2023-09-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | レボドパ送達のための組成物及び方法 |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| CA3196650A1 (en) * | 2020-12-22 | 2022-06-30 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| WO2023126945A1 (en) * | 2022-01-03 | 2023-07-06 | Neuroderm, Ltd. | Methods and compositions for treating parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3961060A (en) * | 1973-05-17 | 1976-06-01 | Astra Lakemedal Aktiebolag | Method and compositions for the treatment of neurological disorders |
| US4409233A (en) * | 1978-07-04 | 1983-10-11 | Sankyo Company, Limited | Highly concentrated preparations of dopa compounds |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769424A (en) * | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| US3936495A (en) * | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) * | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE252290T1 (de) * | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4684666A (en) * | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5350769A (en) * | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
| US5877176A (en) * | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| WO1999048876A1 (en) * | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) * | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| EP1077692B1 (en) * | 1998-05-15 | 2004-07-28 | Warner-Lambert Company LLC | Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same |
| US6274168B1 (en) * | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) * | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) * | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) * | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| EA200401334A1 (ru) * | 2002-04-11 | 2005-04-28 | Ранбакси Лабораторис Лимитед | Фармацевтические композиции карбидопы и леводопы с контролируемым высвобождением |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| ATE463494T1 (de) | 2002-10-10 | 2010-04-15 | Morphochem Ag Komb Chemie | Neue verbindungen mit antibakterieller aktivität |
| US20050147687A1 (en) * | 2003-07-18 | 2005-07-07 | Julia Rashba-Step | Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation |
| US7589233B2 (en) * | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| ATE495739T1 (de) * | 2003-08-29 | 2011-02-15 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| KR20060108692A (ko) * | 2003-10-31 | 2006-10-18 | 알자 코포레이션 | 메트포르민의 개선된 흡수를 위한 조성물 및 제형 |
| CN1901881A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 用于增强的吸收的组合物和剂型 |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| WO2006043532A1 (ja) * | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| MX2008015339A (es) | 2006-05-31 | 2008-12-16 | Solvay Pharm Gmbh | Administracion intestinal a largo plazo durante 24 horas de levodopa/carbidopa. |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| US8563013B2 (en) * | 2007-04-06 | 2013-10-22 | Janssen Biotech, Inc. | Systems and methods for delivering a fluid drug |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| RU2678839C2 (ru) | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| RS57334B1 (sr) | 2010-11-15 | 2018-08-31 | Neuroderm Ltd | Kompozicije za transdermalno davanje aktivnih sredstava |
| PL2640358T3 (pl) | 2010-11-15 | 2018-06-29 | Neuroderm Ltd | Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji |
| SG191090A1 (en) | 2010-12-10 | 2013-07-31 | Synagile Corp | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| BR112015022390A8 (pt) | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| CN106413754B (zh) | 2014-03-13 | 2019-11-29 | 纽罗德姆有限公司 | 多巴脱羧酶抑制剂组合物 |
-
2010
- 2010-05-17 RU RU2015115064A patent/RU2678839C2/ru active
- 2010-05-17 WO PCT/IL2010/000400 patent/WO2010134074A1/en not_active Ceased
- 2010-05-17 PL PL10725880T patent/PL2432454T3/pl unknown
- 2010-05-17 CA CA2761624A patent/CA2761624C/en active Active
- 2010-05-17 DK DK10725880.8T patent/DK2432454T3/en active
- 2010-05-17 PT PT171583602T patent/PT3192500T/pt unknown
- 2010-05-17 EP EP17158360.2A patent/EP3192500B1/en active Active
- 2010-05-17 SG SG10201709016RA patent/SG10201709016RA/en unknown
- 2010-05-17 AU AU2010250766A patent/AU2010250766B2/en active Active
- 2010-05-17 BR BRPI1011031A patent/BRPI1011031B8/pt active IP Right Grant
- 2010-05-17 JP JP2012511409A patent/JP5643297B2/ja active Active
- 2010-05-17 PT PT107258808T patent/PT2432454T/pt unknown
- 2010-05-17 HR HRP20170805TT patent/HRP20170805T1/hr unknown
- 2010-05-17 CN CN201410800432.0A patent/CN104546700B/zh active Active
- 2010-05-17 CN CN201080022208.3A patent/CN102438587B/zh active Active
- 2010-05-17 DK DK17158360.2T patent/DK3192500T3/da active
- 2010-05-17 KR KR1020117030315A patent/KR101641401B1/ko active Active
- 2010-05-17 LT LTEP10725880.8T patent/LT2432454T/lt unknown
- 2010-05-17 SI SI201031466T patent/SI2432454T1/sl unknown
- 2010-05-17 SG SG2011085297A patent/SG176159A1/en unknown
- 2010-05-17 EP EP20197759.2A patent/EP3777839A1/en active Pending
- 2010-05-17 SG SG10201505101VA patent/SG10201505101VA/en unknown
- 2010-05-17 HU HUE10725880A patent/HUE033388T2/en unknown
- 2010-05-17 ES ES17158360T patent/ES2840748T3/es active Active
- 2010-05-17 PL PL17158360T patent/PL3192500T3/pl unknown
- 2010-05-17 KR KR1020167019114A patent/KR101709904B1/ko active Active
- 2010-05-17 RU RU2011149976/15A patent/RU2559083C9/ru active
- 2010-05-17 NZ NZ596963A patent/NZ596963A/en not_active IP Right Cessation
- 2010-05-17 MX MX2011012315A patent/MX2011012315A/es active IP Right Grant
- 2010-05-17 ES ES10725880.8T patent/ES2627655T3/es active Active
- 2010-05-17 US US12/781,357 patent/US8193243B2/en active Active
- 2010-05-17 MX MX2015001674A patent/MX364974B/es unknown
- 2010-05-17 EP EP10725880.8A patent/EP2432454B1/en active Active
- 2010-05-17 HU HUE17158360A patent/HUE052685T2/hu unknown
- 2010-05-19 AR ARP100101735A patent/AR078413A1/es not_active Application Discontinuation
- 2010-07-14 US US12/836,130 patent/US7863336B2/en active Active
- 2010-12-07 US US12/961,534 patent/US9101663B2/en active Active
-
2011
- 2011-11-15 IL IL216383A patent/IL216383A/en active IP Right Grant
- 2011-11-17 CL CL2011002895A patent/CL2011002895A1/es unknown
- 2011-12-08 ZA ZA2011/09037A patent/ZA201109037B/en unknown
-
2014
- 2014-05-13 US US14/276,211 patent/US9040589B2/en active Active
- 2014-05-13 US US14/276,235 patent/US9040590B2/en active Active
- 2014-10-30 JP JP2014221786A patent/JP5921002B2/ja active Active
-
2015
- 2015-07-01 US US14/789,214 patent/US9993451B2/en active Active
-
2016
- 2016-04-08 JP JP2016078121A patent/JP6157678B2/ja active Active
-
2017
- 2017-05-31 CY CY20171100573T patent/CY1119495T1/el unknown
-
2018
- 2018-05-30 US US15/992,979 patent/US20190125708A1/en not_active Abandoned
-
2019
- 2019-01-16 RU RU2019101159A patent/RU2019101159A/ru unknown
- 2019-03-28 AR ARP190100805A patent/AR117412A2/es unknown
- 2019-12-23 AR ARP190103847A patent/AR117502A2/es not_active Application Discontinuation
-
2020
- 2020-04-30 US US16/863,459 patent/US20210077442A1/en not_active Abandoned
- 2020-12-21 HR HRP20202038TT patent/HRP20202038T1/hr unknown
-
2022
- 2022-11-11 US US17/985,556 patent/US20230321019A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3961060A (en) * | 1973-05-17 | 1976-06-01 | Astra Lakemedal Aktiebolag | Method and compositions for the treatment of neurological disorders |
| US4409233A (en) * | 1978-07-04 | 1983-10-11 | Sankyo Company, Limited | Highly concentrated preparations of dopa compounds |
Non-Patent Citations (2)
| Title |
|---|
| DI STEFANO A. et al. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin.Drug Deliv. 2009 Apr; 6(4):389-404 Реферат [on line] [Найдено 06.03.2014] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/19382882). NYHOLM D. Enteral levodopa/carbidopa gel infusion for treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev.Neuroyher. 2006 Oct; 6(10):1403-11 Реферат [on line] [Найдено 05.03.2014] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/17078781). * |
| ЛЕВИН О.С. Диагностика и лечение синдрома беспокойных ног. Лечащий врач, N05.08 [on line] [Найдено 11.03.2014] (Найдено из Интернет: ivrach.ru/2008/05/5154263 Глава Этиология 3-й абзац, Глава Лекарственная терапия абзацы 4-10. ГРЭХАМ-СМИТ Д.Г. и др. Оксфордский справочник по клинической фармакологии и фармакотерапии. М., Медицина, 2000, с.641-642, глава «L-дофа и ингибиторы декарбоксилазы» * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2559083C9 (ru) | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы | |
| RU2607497C2 (ru) | Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции | |
| HK40046868A (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
| HK1168557B (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
| HK1168557A (en) | Compositions for continuous administration of dopa decarboxylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification | ||
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 22-2015 FOR TAG: (54) |